Some cancer drugs, above all trastuzumab deruxtecan, can inflame the lungs. It can show on a scan before there are any symptoms, and it is treated by pausing or stopping the drug and, often, steroids. The rules differ from drug to drug. A new or worsening cough, breathlessness or fever needs a call to your cancer team straight away, not at the next appointment.
Drug-induced ILD is a diagnosis of exclusion: infection, cancer progression, radiation pneumonitis and fluid overload look similar on CT. Grade 1 is a scan finding with no symptoms, grade 2 mild symptoms, grade 3 severe symptoms or a need for oxygen, grade 4 life-threatening. What happens at each grade depends on the drug, and the label of the drug being taken is the rule; the reader's own team's protocol comes first.
How common (US labels): trastuzumab deruxtecan 12% at 5.4 mg/kg, fatal in 0.9%, median onset 5.5 months; datopotamab deruxtecan 7% in lung cancer and 3.0% in breast cancer; osimertinib 4%; abemaciclib about 3%; ribociclib 1.6% in advanced breast cancer; everolimus up to 19%; sotorasib 2.2%; olaparib 1.0%. In a manufacturer-funded pooled analysis of 1150 trial patients on trastuzumab deruxtecan, 87.0% of first events came within 12 months, and the factors potentially associated with higher risk were age under 65, enrolment in Japan, a dose above 6.4 mg/kg, oxygen saturation below 95%, moderate or severe renal impairment, lung comorbidities and more than 4 years since diagnosis.
Grade 1 (no symptoms), side by side. Trastuzumab deruxtecan and datopotamab deruxtecan: withhold until fully resolved, consider prednisolone at 0.5 mg/kg/day or more, and resume at the same dose if resolved within 28 days or one dose level lower if later. Everolimus: continue without changing the dose. Abemaciclib: no dose change at grade 1 or 2. Ribociclib: no interruption at grade 1. Osimertinib: stop permanently once ILD is confirmed, whatever the grade, except after recent chemoradiotherapy, where grade 1 may be continued or interrupted and restarted. Sotorasib and olaparib: withhold on suspicion and stop permanently if confirmed.
Grade 2 and above. Deruxtecan conjugates: stop permanently and start prednisolone at 1 mg/kg/day or more for at least 14 days, then taper over at least 4 weeks. Osimertinib, sotorasib, olaparib: stopped. Everolimus: withhold at grade 2 or 3 and resume at half dose after improvement, stop at grade 4. Abemaciclib: withhold for persistent or recurrent grade 2 and resume one dose lower, stop at grade 3 or 4. Ribociclib: interrupt at grade 2 and consider a lower dose, stop at grade 3 or 4.
The expert opinion of Conte and colleagues (ESMO Open 2022, funded by Daiichi Sankyo and AstraZeneca, ungraded) adds a work-up (high-resolution CT at once, oxygen saturation, bloods, microbiology, lung function, bronchoscopy when the picture is unclear), prednisone 1 to 2 mg/kg/day at grade 2, methylprednisolone 1 to 2 mg/kg/day at grade 3, pulsed methylprednisolone 500 to 1000 mg/day for 3 days as an option at grade 4, and says infliximab, tocilizumab, mycophenolate or intravenous immunoglobulin may be considered at grade 3 if there is no improvement within 48 to 72 hours (at grade 4, infliximab, mycophenolate or immunoglobulin after 48 hours without improvement). It says the efficacy of steroids is not clearly established.
Why: The panel asks for the risk to be weighed before any anticancer drug is started. In the pooled trastuzumab deruxtecan trials, existing lung conditions and moderate or severe kidney impairment were among the factors potentially linked with a higher risk.
“Before the start of any anticancer therapy, physicians should carefully evaluate the risk for DIILD”
Why: A later change can only be judged against where the person started.
“(ii) the baseline evaluation of respiratory function (i.e. spirometry) in addition to vital signs, physical examination and chest imaging”
Why: The label asks for these symptoms to be investigated promptly, and the expert panel says that finding the inflammation early could favour a better outcome.
“Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms.”
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026
Why: The expert panel says up to a third of people with drug-induced ILD have no symptoms, so it may be found on a scan. In the pooled trastuzumab deruxtecan trials, reviewers dated the onset earlier than the treating doctor had for 53.2% of events.
“Monitor patients for pulmonary symptoms indicative of ILD or pneumonitis. Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams.”
Eli Lilly, on DailyMed (US National Library of Medicine) 2026
Why: These labels each say to interrupt or withhold on suspicion. The everolimus label continues treatment when there are few or no symptoms, and the abemaciclib label asks for no change at grade 1.
“In patients who have new or worsening respiratory symptoms suspected to be due to ILD or pneumonitis, interrupt KISQALI immediately and evaluate the patient.”
Novartis, on DailyMed (US National Library of Medicine) 2026
Why: The panel says a comparison with the person's own earlier values is always decisive, because oxygen levels can fall while still inside the normal range.
“When DIILD is suspected, vital signs should be routinely monitored, particularly the respiratory rate to detect tachypnoea and oxygen saturation by pulse oximetry (SpO2), the latter being extremely relevant in patients with dyspnoea.”
Why: The panel calls high-resolution CT the most sensitive test for finding ILD from its early stages, and it can show how much of the lung is involved.
“HRCT is recommended immediately after the medical examination.”
Why: The expert panel lists infection, radiation pneumonitis, bleeding into the lung, fluid on the lung and, more rarely, cancer spreading through the lung as conditions that overlap with drug-induced ILD.
“Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations.”
Eli Lilly, on DailyMed (US National Library of Medicine) 2026
Why: Washings from the lung can find an infection, bleeding or cancer spread that a scan cannot tell apart from drug injury.
“BAL should be considered when there is a lack of clinical improvement on withdrawal of the causative drug, despite corticosteroid therapy, or when the differential diagnosis is inconclusive.”
Why: The labels pause these drugs even when there are no symptoms. If it resolves within 28 days treatment restarts at the same dose, and if it takes longer, one dose level lower.
“For asymptomatic (Grade 1) ILD, consider corticosteroid treatment (e.g., ≥0.5 mg/kg/day prednisolone or equivalent). Withhold ENHERTU until recovery”
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026
Why: The label notes that imaging appears to overestimate how often clinical pneumonitis occurs.
“Continue AFINITOR/AFINITOR DISPERZ without dose alteration in patients who develop radiological changes suggestive of non-infectious pneumonitis and have few or no symptoms.”
Novartis, on DailyMed (US National Library of Medicine) 2026
Why: The label says lung inflammation from this drug can be severe and fatal, and it allows a restart only at grade 1 after recent chemoradiotherapy.
“Permanently discontinue TAGRISSO if ILD/pneumonitis is confirmed”
AstraZeneca, on DailyMed (US National Library of Medicine) 2026
Why: This is the rule in the label's boxed warning. The labels give no way to restart either drug once there have been symptoms.
“Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis.”
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026
Why: The labels give this as their example regimen. The expert panel says that tapering too fast may reactivate the disease, and also that how well steroids work is not clearly established.
“In cases of symptomatic ILD (Grade 2 or greater), promptly initiate systemic corticosteroid treatment (e.g., ≥1 mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks.”
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026
Why: The label asks for no dose change at grade 1, or at grade 2 that settles within 7 days with supportive measures, and stops the drug in severe cases, some of which have been fatal.
“Withhold or reduce dose for patients who develop persistent or recurrent Grade 2 ILD or pneumonitis. Permanently discontinue VERZENIO in all patients with Grade 3 or 4 ILD or pneumonitis”
Eli Lilly, on DailyMed (US National Library of Medicine) 2026
Why: The panel says severe symptoms may lead to a hospital stay. For grade 4 it describes urgent hospital treatment with intravenous steroids (usually methylprednisolone or prednisolone 2 mg/kg a day, or a pulse of methylprednisolone 500 to 1000 mg a day for 3 days), oxygen and sometimes ventilation.
“In grade 3 DIILD, the timely and definitive discontinuation of the anticancer drug and the initiation of corticosteroid therapy at 1-2 mg/kg/day of methylprednisolone or equivalent are essential.”
Why: The scan shows whether treatment is working and, for some drugs, whether treatment may restart.
“A follow-up CT scan should be repeated 2 weeks after the initial diagnosis of DIILD, although the time interval can be adjusted depending on the patient’s overall clinical course.”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Teaching and immediate reporting of symptoms, high-resolution CT on suspicion, a hold on suspicion where the label asks for one, exclusion of infection and other causes, and then the product label's rule for the grade. The labels do not agree, and all are shown. At grade 1: deruxtecan conjugates are withheld until resolved with steroids considered; everolimus, abemaciclib and ribociclib continue; osimertinib, sotorasib and olaparib stop once ILD is confirmed (osimertinib may continue at grade 1 after chemoradiotherapy). At grade 2: deruxtecan conjugates stop permanently; everolimus and ribociclib are withheld and may resume at a lower dose after recovery; abemaciclib continues unless grade 2 persists or recurs, when it is withheld and resumed one dose lower. The expert opinion of Conte and colleagues (funded by Daiichi Sankyo and AstraZeneca; ungraded) advises stopping the causative drug at grade 1 in general, says continuation can be considered in selected cases for checkpoint inhibitors, mTOR inhibitors and, by its authors' own opinion, tyrosine kinase inhibitors, which is more permissive than the osimertinib label, and says steroids are not generally needed at grade 1, where the trastuzumab deruxtecan label says to consider them. No source read cites a randomised comparison of these rules.
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · AstraZeneca, on DailyMed (US National Library of Medicine) 2026 · Eli Lilly, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2026 · Amgen, on DailyMed (US National Library of Medicine) 2026 · AstraZeneca, on DailyMed (US National Library of Medicine) 2025 · ESMO Open (Conte et al.; a panel of 14 Italian experts, not an ESMO guideline; publication, workshops and medical writing funded by Daiichi Sankyo S.p.A. and AstraZeneca S.p.A.) 2022
Where it differs: Trastuzumab deruxtecan and datopotamab deruxtecan: withhold until resolved to grade 0; same dose if resolved in 28 days or less, one dose level lower if longer; consider corticosteroids. Everolimus: continue without dose alteration. Abemaciclib: no dosage modification at grade 1 or 2. Ribociclib: no interruption; start appropriate medical therapy and monitor. Osimertinib: permanently discontinue if confirmed; after recent definitive platinum-based chemoradiotherapy, withhold or continue at grade 1 as clinically indicated. Sotorasib: withhold if suspected, permanently discontinue if confirmed and no other cause is found. Olaparib: interrupt if suspected, discontinue if confirmed.
Evidence: Regulatory labels, each from its own trials. The everolimus label notes that imaging appears to overestimate the incidence of clinical pneumonitis. Conte and colleagues say that no robust scientific evidence is available to guide the decision to continue at grade 1.
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2026 · Eli Lilly, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2026 · AstraZeneca, on DailyMed (US National Library of Medicine) 2026 · Amgen, on DailyMed (US National Library of Medicine) 2026 · AstraZeneca, on DailyMed (US National Library of Medicine) 2025 · ESMO Open (Conte et al.; a panel of 14 Italian experts, not an ESMO guideline; publication, workshops and medical writing funded by Daiichi Sankyo S.p.A. and AstraZeneca S.p.A.) 2022
Where it differs: Deruxtecan conjugates: permanently discontinue at grade 2 or higher. Osimertinib: permanently discontinue at grade 2 or higher in every setting. Everolimus: withhold at grade 2 until grade 0 or 1 and resume at 50% of the previous dose, stopping if there is no improvement within 4 weeks; the same at grade 3, stopping if grade 3 recurs; stop at grade 4. Abemaciclib: withhold for grade 2 that does not resolve within 7 days with maximal supportive measures, or recurs, and resume at the next lower dose; discontinue at grade 3 or 4. Ribociclib: interrupt at grade 2 until grade 1 or less and consider the next lower dose, stopping if grade 2 recurs; discontinue at grade 3 or 4.
Evidence: Regulatory labels. Conte and colleagues (ungraded expert opinion, funded by Daiichi Sankyo and AstraZeneca) say that in most cases the drug should be stopped permanently after grade 2, and that rechallenge should be considered if the drug had given remarkable benefit, the ILD has resolved completely on symptoms and scan, risk factors for recurrence are limited, and the drug is a checkpoint inhibitor, an mTOR inhibitor or one of most targeted agents, but not trastuzumab deruxtecan.
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · AstraZeneca, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2026 · Eli Lilly, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2026 · ESMO Open (Conte et al.; a panel of 14 Italian experts, not an ESMO guideline; publication, workshops and medical writing funded by Daiichi Sankyo S.p.A. and AstraZeneca S.p.A.) 2022
Where it differs: Trastuzumab deruxtecan and datopotamab deruxtecan labels: consider prednisolone 0.5 mg/kg/day or more at grade 1; 1 mg/kg/day or more at grade 2 or higher for at least 14 days, then a taper over at least 4 weeks. Conte and colleagues: steroids not generally needed at grade 1 (0.5 mg/kg/day of prednisone or equivalent should be considered if steroids are judged appropriate, as with trastuzumab deruxtecan, then a taper over at least 4 weeks); prednisone 1 to 2 mg/kg/day at grade 2, tapered over 4 to 6 weeks in those who respond well; methylprednisolone 1 to 2 mg/kg/day at grade 3 with a taper after 8 to 12 weeks; severe pneumonia is usually treated with intravenous methylprednisolone or prednisolone 2 mg/kg/day, and at grade 4 a pulse of methylprednisolone 500 to 1000 mg/day for 3 days, followed by prednisolone 1 to 2 mg/kg/day for 2 to 4 weeks, should also be considered. For people on trastuzumab deruxtecan the panel repeats the label's 1 mg/kg/day or more of prednisolone at grades 2 and 3. Everolimus label: corticosteroids may be indicated until symptoms resolve, with Pneumocystis prophylaxis while they are given. The other labels read give no steroid dose.
Evidence: No controlled trial of steroid dose or duration in drug-induced ILD was cited by any source read. Conte and colleagues state that the efficacy of corticosteroids is not clearly established.
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2026 · ESMO Open (Conte et al.; a panel of 14 Italian experts, not an ESMO guideline; publication, workshops and medical writing funded by Daiichi Sankyo S.p.A. and AstraZeneca S.p.A.) 2022
Where it differs: The label allows a restart once a grade 1 event has resolved to grade 0. In the pooled trials fewer than a quarter of such patients were retreated.
Evidence: A pooled analysis of nine trials (Rugo and colleagues 2025, abstract read; funders listed as AstraZeneca and Daiichi Sankyo): of 193 patients with a grade 1 event, 45 (23.3%) were retreated; ILD came back in 15 (33.3%), all grade 1 or 2, at a median of 64 days. Uncontrolled, and the retreated patients were selected.
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · Annals of Oncology (Rugo et al.; Europe PMC lists AstraZeneca and Daiichi Sankyo as funders) 2025
Where it differs: For people who have had recent definitive platinum-based chemoradiotherapy, the label allows osimertinib to be continued, or interrupted and restarted, at grade 1; everyone else stops permanently once ILD is confirmed.
Evidence: In the LAURA study ILD or pneumonitis, including radiation pneumonitis, was reported in 56% of 143 patients on osimertinib and 38% of 73 on placebo; of 46 patients rechallenged, 11% had a recurrence (label).
AstraZeneca, on DailyMed (US National Library of Medicine) 2026
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Trastuzumab deruxtecan: permanent stop at grade 2 or higher (boxed warning) “Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis.” | Regulatory label; not graded | Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 |
| Datopotamab deruxtecan: withhold on suspicion, permanent stop if grade 2 or higher is confirmed “Withhold DATROWAY in patients with suspected ILD/pneumonitis and permanently discontinue DATROWAY if ≥Grade 2 ILD/pneumonitis is confirmed” | Regulatory label; not graded | Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 |
| Osimertinib after chemoradiotherapy: grade 1 may continue or be interrupted and restarted “For patients who have received recent definitive platinum-based chemoradiation therapy with Grade 1 ILD/pneumonitis continue TAGRISSO or interrupt and restart, as appropriate.” | Regulatory label; not graded | AstraZeneca, on DailyMed (US National Library of Medicine) 2026 |
| Everolimus: withhold or stop for grade 2 to 4, with Pneumocystis prophylaxis when steroids are needed “Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required.” | Regulatory label; not graded | Novartis, on DailyMed (US National Library of Medicine) 2026 |
| Ribociclib: no interruption at grade 1 “No dose interruption or adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.” | Regulatory label; not graded | Novartis, on DailyMed (US National Library of Medicine) 2026 |
| Sotorasib: withhold on suspicion, stop permanently if no other cause is found “Withhold LUMAKRAS if ILD/pneumonitis is suspected.” | Regulatory label; not graded | Amgen, on DailyMed (US National Library of Medicine) 2026 |
| Olaparib: interrupt on suspicion, discontinue if confirmed “If pneumonitis is confirmed, discontinue Lynparza treatment and treat the patient appropriately.” | Regulatory label; not graded | AstraZeneca, on DailyMed (US National Library of Medicine) 2025 |
| At grade 1, continuation can be considered for mTOR inhibitors and, in the authors' opinion, tyrosine kinase inhibitors; antibody-drug conjugates should be stopped until resolution “Specifically, continuation can be considered for ICIs and mTOR inhibitors (and also tyrosine kinase inhibitors by our expert opinion), whereas ADCs such as T-DXd should be discontinued until resolution.” | Expert opinion; not graded (funded by Daiichi Sankyo and AstraZeneca) | ESMO Open (Conte et al.; a panel of 14 Italian experts, not an ESMO guideline; publication, workshops and medical writing funded by Daiichi Sankyo S.p.A. and AstraZeneca S.p.A.) 2022 |
| Steroids are not generally needed at grade 1 “Steroid therapy is not generally needed for grade 1 DIILD; moreover, steroids may have a negative impact on survival if the patient is treated with ICIs.” | Expert opinion; not graded (funded by Daiichi Sankyo and AstraZeneca) | ESMO Open (Conte et al.; a panel of 14 Italian experts, not an ESMO guideline; publication, workshops and medical writing funded by Daiichi Sankyo S.p.A. and AstraZeneca S.p.A.) 2022 |
| The efficacy of corticosteroids is not clearly established “The efficacy of corticosteroids is not clearly established, given the widespread practice of discontinuing the pneumotoxic drug when starting steroid therapy.” | Expert opinion; not graded (funded by Daiichi Sankyo and AstraZeneca) | ESMO Open (Conte et al.; a panel of 14 Italian experts, not an ESMO guideline; publication, workshops and medical writing funded by Daiichi Sankyo S.p.A. and AstraZeneca S.p.A.) 2022 |
| Treatment need not wait for every other cause to be excluded in severe cases “Since early treatment of DIILD is critical for improved outcome, a definitive diagnosis (by means of exclusion of all the alternative aetiologies) is not always mandatory before the start of steroid treatment, especially in severe cases (grade 3 and 4).” | Expert opinion; not graded (funded by Daiichi Sankyo and AstraZeneca) | ESMO Open (Conte et al.; a panel of 14 Italian experts, not an ESMO guideline; publication, workshops and medical writing funded by Daiichi Sankyo S.p.A. and AstraZeneca S.p.A.) 2022 |
| Too fast a steroid taper can reactivate the disease “Early interruption of steroid treatment or an excessively fast tapering may reactivate the disease.” | Expert opinion; not graded (funded by Daiichi Sankyo and AstraZeneca) | ESMO Open (Conte et al.; a panel of 14 Italian experts, not an ESMO guideline; publication, workshops and medical writing funded by Daiichi Sankyo S.p.A. and AstraZeneca S.p.A.) 2022 |
| Most first events on trastuzumab deruxtecan come in the first 12 months “Overall, 87.0% (154/177) had a first adjudicated drug-related ILD/pneumonitis event within 12 months of starting T-DXd” | Pooled analysis of trials; not graded (supported by AstraZeneca and Daiichi Sankyo) | ESMO Open (Powell et al.; supported by AstraZeneca and Daiichi Sankyo, medical writing funded by AstraZeneca) 2022 |
| ILD recurred in a third of patients retreated with trastuzumab deruxtecan after grade 1, all grade 1 or 2 “ILD recurred in one-third of patients; all recurrence events were grade 1/2 and manageable using existing treatment guidelines.” | Pooled analysis of trials; not graded (funders listed as AstraZeneca and Daiichi Sankyo) | Annals of Oncology (Rugo et al.; Europe PMC lists AstraZeneca and Daiichi Sankyo as funders) 2025 |
Shares Radiation pneumonitis and lung fibrosis, Pneumonitis, Interstitial lung disease (ILD) / pneumonitis.
Shares Ribociclib, Abemaciclib, Everolimus.
Shares Interstitial lung disease (ILD) / pneumonitis, Datopotamab deruxtecan, Trastuzumab deruxtecan.
Shares Ribociclib, Abemaciclib, Everolimus.
Shares Pneumonitis, Immune-related pneumonitis from checkpoint inhibitors, by grade.
Shares CTCAE toxicity grading (grade 3-4 adverse events), Ribociclib, Sotorasib, Abemaciclib.
Shares Abemaciclib, Everolimus.
Shares Interstitial lung disease (ILD) / pneumonitis, Trastuzumab deruxtecan.